Daptomycin-Loaded Lipid Nanoparticles with Intrinsic Antimicrobial Activity against S. aureus

Marc Martínez-Miguel – Research Technician, ICMAB-CSIC; Marta Alcaina Hernando – R&D Scientist, Nanomol Technologies S.L.; Anna Arís – Permanent Researcher, Institut de Recerca I Tecnologia Agroalimentàries (IRTA); Elena Garcia-Fruitós – Permanent Researcher, Institut de Recerca I Tecnologia Agroalimentàries (IRTA); Alba Córdoba – Business Development Director and coordinator of Technology Transfer and scale-up activities, Nanomol Technologies S.L.; Imma Ratera – Permanent Researcher, ICMAB-CSIC

Introduction:

Antimicrobial resistance is a global health challenge responsible for more than 1 million deaths worldwide each year (1). This highlights the urgent need for new antimicrobial strategies. Daptomycin, a clinically used peptide-based antimicrobial, remains sensitive to its physicochemical environment, which affects its activity and performance (2). It is used here as a model system to explore formulation strategies for peptide-based antimicrobials, often associated with reduced resistance development (3). Lipid-based nanoparticles (LNPs) with intrinsic antimicrobial activity offer a promising platform to stabilize such actives and combine antimicrobial effects.